Contributors |
|
xvii | |
Foreword |
|
xxiii | |
Preface |
|
xxv | |
|
Part I Genetic aspects of depression |
|
|
|
1 Epigenetics in depression |
|
|
3 | (12) |
|
|
|
|
|
|
|
3 | (1) |
|
|
4 | (1) |
|
Early-life events, DNA methylation, and depression |
|
|
5 | (1) |
|
Different gene methylation profiles in depression models |
|
|
5 | (1) |
|
|
6 | (1) |
|
Histone acetylation and depression |
|
|
6 | (1) |
|
Histone methylation and depression |
|
|
6 | (2) |
|
HDAC inhibitors as antidepressants |
|
|
8 | (1) |
|
Histone modification associated with gestational stress and gender differences |
|
|
8 | (1) |
|
miRNA mechanisms of action |
|
|
8 | (1) |
|
mIRNAs and neuroplasticity in depression |
|
|
9 | (1) |
|
miRNAs and animal models of depression |
|
|
9 | (1) |
|
miRNAs and postmortem brain |
|
|
9 | (1) |
|
miRNAs as a peripheral markers of depression |
|
|
9 | (1) |
|
|
10 | (1) |
|
|
11 | (4) |
|
2 Genes, depression, and nuclear DNA |
|
|
15 | (10) |
|
|
|
|
15 | (1) |
|
Heritability of depression |
|
|
16 | (1) |
|
Heterogeneity of depression |
|
|
16 | (1) |
|
The multifactorial background of depression |
|
|
16 | (1) |
|
The candidate gene approach in depression |
|
|
17 | (1) |
|
Genome-wide analytical studies (GWAS) in depression |
|
|
18 | (1) |
|
Phenotyping of depression in genetic studies |
|
|
19 | (1) |
|
Genetic architecture of depression |
|
|
19 | (1) |
|
Implications of genetic studies of depression for clinical practice |
|
|
20 | (1) |
|
|
21 | (1) |
|
|
22 | (3) |
|
3 Gene expression in depression: Molecular aspects of postpartum depression |
|
|
25 | (12) |
|
|
|
25 | (1) |
|
What is known about PPD etiology? |
|
|
25 | (1) |
|
Molecular biology approaches for the study of PPD: The experimental models |
|
|
26 | (1) |
|
Genetic factors for PPD: The female reproductive hormones |
|
|
26 | (1) |
|
Genetic factors for PPD: The neuropeptides and mood modulators |
|
|
26 | (2) |
|
Genetic factors for PPD: The HPA axis |
|
|
28 | (1) |
|
Genetic factors for PPD: The immunoinflammatory response |
|
|
29 | (1) |
|
Genetic factors for PPD: The microarray studies |
|
|
29 | (1) |
|
Genetic factors for PPD: The epigenetics |
|
|
30 | (2) |
|
The importance of the molecular markers for the PPD diagnosis |
|
|
32 | (1) |
|
|
33 | (4) |
|
4 Genetics and epigenetics of the SLC6A4 gene in depression |
|
|
37 | (10) |
|
|
|
|
|
37 | (1) |
|
The role of the serotoninergic system in neurodevelopment depression |
|
|
38 | (1) |
|
Genetic variations in the serotonin transporter gene and the risk for depression |
|
|
39 | (1) |
|
Stress events and epigenetic changes |
|
|
40 | (2) |
|
DNA methylation in the SLC6A4 gene and depression |
|
|
40 | (1) |
|
miRNA targeting serotonin transporter |
|
|
41 | (1) |
|
|
42 | (1) |
|
Perspectives on the SLC6A4 contribution for depression etiology |
|
|
42 | (1) |
|
|
43 | (4) |
|
5 Molecular basis of tryptophan metabolism disorders associated with depression |
|
|
47 | (12) |
|
|
|
|
|
47 | (1) |
|
Genetic background of disorders of tryptophan metabolism in depression |
|
|
48 | (3) |
|
Depression and localization of TRYCATs genes |
|
|
48 | (1) |
|
Molecular aspects of TRYCAT enzyme disorders in the course of depression |
|
|
48 | (2) |
|
Genetic aspects of neurotransmitter disorders in the course of depression |
|
|
50 | (1) |
|
Disorders of tryptophan metabolism and antidepressant therapy |
|
|
51 | (1) |
|
Compensatory (anti)inflammatory reflex system in depression |
|
|
52 | (1) |
|
Disorders of tryptophan metabolism in the development of postpartum depression |
|
|
52 | (2) |
|
|
54 | (1) |
|
|
54 | (5) |
|
6 Metalloproteinases genes and their relationship with depression |
|
|
59 | (10) |
|
|
|
|
|
|
|
59 | (1) |
|
|
59 | (1) |
|
Structure, history, classification, and regulation |
|
|
59 | (1) |
|
|
60 | (2) |
|
Pathophysiology of depression |
|
|
62 | (2) |
|
|
64 | (1) |
|
|
65 | (1) |
|
|
65 | (4) |
|
7 Linking gene regions jointly with environment and depression |
|
|
69 | (10) |
|
|
|
|
69 | (1) |
|
Candidate gene methods in GxE research |
|
|
69 | (1) |
|
Gene-region analyses: A primer |
|
|
70 | (1) |
|
|
71 | (1) |
|
Gene-region analyses in depression research |
|
|
72 | (1) |
|
Challenges and future directions |
|
|
73 | (1) |
|
|
74 | (5) |
|
Part II Molecular and cellular effects of depression |
|
|
|
8 Linking depression, mRNA translation, and serotonin |
|
|
79 | (10) |
|
|
|
|
|
|
|
Fatimeh-Frouh Taghavi-Abkuh |
|
|
|
|
|
|
|
79 | (2) |
|
Major depressive disorder |
|
|
79 | (1) |
|
Serotonergic neurotransmission in MDD |
|
|
80 | (1) |
|
Selective serotonin reuptake inhibitors (SSRIs) |
|
|
81 | (1) |
|
mRNA translation: A central process in regulating gene expression |
|
|
81 | (3) |
|
elF4E phosphorylation controls brain inflammation, 5-HT neurotransmission, and depressive symptoms |
|
|
82 | (2) |
|
Dysregulated inflammation in MDD |
|
|
84 | (1) |
|
|
85 | (1) |
|
|
86 | (3) |
|
9 Changes in cortical gene expression in major depressive disorders: More evidence implicating inflammatory-related pathways in disease etiology |
|
|
89 | (12) |
|
|
Cortical dysfunction in major depressive disorders |
|
|
89 | (1) |
|
Gene x environment interactions in major depressive disorders |
|
|
89 | (1) |
|
Cortical gene expression in major depressive disorders |
|
|
90 | (1) |
|
Regional changes in cortical gene expression in major depressive disorders |
|
|
90 | (1) |
|
Changes in gene expression in the frontopolar cortex |
|
|
90 | (4) |
|
Changes in gene expression in the orbitofrontal cortex |
|
|
94 | (1) |
|
Changes in gene expression in the dorsolateral prefrontal cortex |
|
|
94 | (1) |
|
Changes in gene expression in the ventrolateral prefrontal cortex |
|
|
95 | (1) |
|
Changes in gene expression in the cingulated cortex |
|
|
95 | (1) |
|
Changes in gene expression in the premotor and primary motor cortices |
|
|
95 | (1) |
|
Changes in gene expression in the temporal cortex |
|
|
95 | (1) |
|
Changes in gene expression in the pre-visual cortex |
|
|
96 | (1) |
|
Summary of changed cortical gene expression in major depressive disorders |
|
|
96 | (1) |
|
From transcriptomics to a biology of major depressive disorders |
|
|
96 | (2) |
|
|
98 | (1) |
|
|
98 | (3) |
|
10 FKBP5 gene expression as a biomarker for treatment outcome in depression |
|
|
101 | (6) |
|
|
Depression--A stress-related mental disorder |
|
|
101 | (1) |
|
Role of FKBP5 in stress response regulation and mood disorders |
|
|
102 | (1) |
|
FKBP5 gene expression and antidepressant treatment outcome |
|
|
102 | (1) |
|
FKBP5 as a promising antidepressant drug target |
|
|
103 | (2) |
|
|
105 | (2) |
|
11 Neuroimaging a cytokine storm by transducing IL-1oc to hippocampal cornu ammonis: COVID-19 SARS-CoV-2 |
|
|
107 | (12) |
|
|
|
|
107 | (1) |
|
|
108 | (2) |
|
The BRODERICK PROBE® is a biomedical sensing device |
|
|
108 | (1) |
|
Oh! the fever! Distinguishing intense 5-HT/NE signals from IL-1 a and the 5-HT/NE signals for adaptation by the atypical antidepressant, alprazolam |
|
|
109 | (1) |
|
How we separated the mechanisms of stress from the mechanisms of depression! Two genetically distinct species were studied |
|
|
109 | (1) |
|
Norepinephrine/serotonergic mechanisms in the septohippocampal circuit |
|
|
110 | (1) |
|
Interleukins, memory, and the hippocampus |
|
|
110 | (1) |
|
|
110 | (1) |
|
What were the differences? |
|
|
110 | (1) |
|
Nanobiotechnology model: The device and the circuits |
|
|
110 | (5) |
|
|
115 | (1) |
|
|
115 | (2) |
|
|
117 | (2) |
|
12 Linking interleukin-6 and depression |
|
|
119 | (8) |
|
|
|
|
119 | (1) |
|
Interlinking interleukin-6 and depression |
|
|
119 | (1) |
|
|
119 | (1) |
|
|
120 | (1) |
|
|
120 | (1) |
|
Clinical studies of immune system disorders or immunoactive treatments |
|
|
121 | (1) |
|
Clinical studies of patients with MDD or other depressive disorders |
|
|
121 | (1) |
|
Clinical treatments involving blockade of IL-6 activity |
|
|
122 | (1) |
|
Mechanisms of interaction of IL-6 and depression |
|
|
122 | (1) |
|
|
122 | (1) |
|
|
123 | (1) |
|
|
123 | (1) |
|
|
123 | (4) |
|
13 The role of inflammatory signaling in comorbid depression and epilepsy |
|
|
127 | (12) |
|
Jana Dimitrova Tchekalarova |
|
|
|
|
|
127 | (1) |
|
Inflammation in depression and epilepsy |
|
|
128 | (1) |
|
|
128 | (1) |
|
The activated hypothalamic-pituitary-adrenal axis |
|
|
129 | (1) |
|
|
129 | (1) |
|
The role of inflammation in epilepsy and depression comorbidity |
|
|
129 | (3) |
|
|
129 | (2) |
|
Hyperactivity of HPA axis |
|
|
131 | (1) |
|
Activated microglia and astrocytes |
|
|
131 | (1) |
|
|
132 | (1) |
|
|
132 | (3) |
|
|
135 | (4) |
|
14 Brain inflammasomes in depression |
|
|
139 | (10) |
|
|
|
|
139 | (1) |
|
Inflammasomes, structure-function relationship and role in brain diseases |
|
|
140 | (1) |
|
Major depressive disorders |
|
|
141 | (1) |
|
Linking depressive disorders to neuroinflammation |
|
|
142 | (1) |
|
Inflammasomes are key players in MDD |
|
|
143 | (1) |
|
|
144 | (1) |
|
|
144 | (5) |
|
15 Inflammatory factors and depression in substance use disorder |
|
|
149 | (12) |
|
|
|
|
|
|
|
|
Fernando Rodriguez de Fonseca |
|
|
|
|
149 | (1) |
|
|
150 | (2) |
|
|
150 | (1) |
|
|
150 | (1) |
|
|
151 | (1) |
|
Health consequences of substance use disorder |
|
|
152 | (1) |
|
Comorbidity: Substance use disorder and depression |
|
|
152 | (2) |
|
Primary and substance-induced depression |
|
|
152 | (1) |
|
Dopamine a link between substance use disorder and depression in the brain |
|
|
153 | (1) |
|
Inflammation in substance use disorder and depression |
|
|
154 | (3) |
|
NF-kB pathway and release of proinflammatory factors |
|
|
154 | (2) |
|
Inflammation in the periphery and neuroendocrine pathways |
|
|
156 | (1) |
|
Neuroinflammation and effects on neurotransmission |
|
|
157 | (1) |
|
Conclusions and identification of inflammatory biomarkers |
|
|
157 | (2) |
|
|
159 | (2) |
|
16 Linking Huntington disease, brain-derived, neurotrophic factor, and depressive-like behaviors |
|
|
161 | (18) |
|
|
Cristine de Paula Nascimento-Castro |
|
|
|
|
|
|
161 | (1) |
|
|
161 | (1) |
|
|
162 | (1) |
|
Neuropsychiatric features |
|
|
162 | (1) |
|
Brain-derived neurotrophic factor |
|
|
162 | (1) |
|
The role of brain-derived neurotrophic factor in depression |
|
|
163 | (1) |
|
Alterations of brain-derived neurotrophic factor signaling in HD |
|
|
163 | (5) |
|
Relationship between brain-derived neurotrophic factor and huntingtin |
|
|
163 | (1) |
|
BDNF deficits in HD animal models |
|
|
163 | (5) |
|
BDNF deficits in HD patients |
|
|
168 | (1) |
|
Depression in HD: A putative role for brain-derived neurotrophic factor |
|
|
168 | (4) |
|
Relationship between BDNF levels and depression in HD |
|
|
168 | (1) |
|
Protective effects of BDNF expression in HD mouse models |
|
|
168 | (4) |
|
|
172 | (1) |
|
|
173 | (6) |
|
17 Depression and the NMDA receptor/NO/cGMP pathway |
|
|
179 | (10) |
|
Joao Ronielly Campelo Araujo |
|
|
Ana Cristina de Oliveira Monteiro-Moreira |
|
|
|
179 | (1) |
|
The glutamatergic system and the L-arginine/NO/cGMP pathway |
|
|
180 | (1) |
|
NMDA receptor/NO/cGMP pathway as therapeutic target for depression |
|
|
181 | (1) |
|
NMDA receptor antagonists |
|
|
182 | (1) |
|
Broad glutamatergic modulators |
|
|
182 | (1) |
|
NR2B subunit NMDA-selective antagonist |
|
|
183 | (1) |
|
L-arginine/NO/cGMP pathway inhibitors |
|
|
183 | (1) |
|
Prospects and future directions |
|
|
183 | (1) |
|
|
184 | (1) |
|
|
185 | (4) |
|
18 Translocator protein (18 kDaTSPO) binding in depression |
|
|
189 | (8) |
|
|
Introduction: The inflammatory theory of depression |
|
|
189 | (1) |
|
Postmortem studies and central markers of inflammation |
|
|
189 | (1) |
|
The translocator protein: A putative marker of neuroinflammation |
|
|
190 | (1) |
|
In vivo imaging of neuroinflammation in MDD: Initial findings, controversies, and clinical implications |
|
|
190 | (1) |
|
TSPO binding and cognitive functions in depression |
|
|
191 | (1) |
|
TSPO binding and response to psychotherapy |
|
|
192 | (1) |
|
Limitations and future directions |
|
|
193 | (2) |
|
|
195 | (2) |
|
19 Axonal transport proteins: What they are and how they relate to depressive behaviors |
|
|
197 | (18) |
|
|
|
What is axonal transport? |
|
|
197 | (2) |
|
|
199 | (1) |
|
|
199 | (1) |
|
Axonal transport and brain function |
|
|
199 | (7) |
|
The mRNA and cytosolic proteins |
|
|
199 | (1) |
|
The neurotrophin distribution |
|
|
199 | (5) |
|
|
204 | (1) |
|
Mitochondrial axonal transport |
|
|
204 | (1) |
|
Plasticity and synaptogenesis |
|
|
205 | (1) |
|
|
206 | (1) |
|
Axonal transport proteins and neuroinflammation |
|
|
206 | (1) |
|
Axonal transport proteins and neurodegeneration |
|
|
207 | (1) |
|
Axonal transport proteins and depressive-like behavior |
|
|
207 | (2) |
|
|
207 | (1) |
|
|
208 | (1) |
|
|
208 | (1) |
|
|
208 | (1) |
|
The neurodegenerative conditions |
|
|
208 | (1) |
|
|
208 | (1) |
|
|
208 | (1) |
|
|
208 | (1) |
|
|
209 | (1) |
|
Glucocorticoids and their receptors |
|
|
209 | (1) |
|
|
209 | (1) |
|
|
210 | (5) |
|
20 Molecular features of adenylyl cyclase isoforms and cAMP signaling: A link between adenylyl cyclise 7 and depression |
|
|
215 | (10) |
|
|
|
|
|
|
215 | (1) |
|
Overview of adenylyl cyclases |
|
|
215 | (1) |
|
cAMP signaling and depression |
|
|
216 | (3) |
|
|
219 | (1) |
|
Adenylyl cyclise 7 and depression |
|
|
219 | (2) |
|
|
221 | (1) |
|
|
221 | (1) |
|
|
222 | (3) |
|
21 Neurobiology of depression: The role of glycogen synthase kinase 3 |
|
|
225 | (10) |
|
|
|
|
|
|
|
|
225 | (1) |
|
Posttranslational mechanisms regulating GSK3 activity |
|
|
225 | (1) |
|
GSK3|S in mood disorders and depression |
|
|
226 | (1) |
|
GSK3 and experimental models of depression-like behaviors |
|
|
226 | (1) |
|
Role of GSK3 in regulating intrinsic excitability |
|
|
227 | (1) |
|
GSK3 and voltage-gated sodium (Nav) channels |
|
|
227 | (1) |
|
GSK3 and accessory proteins of the voltage-gated sodium (Nav) channel complex |
|
|
227 | (1) |
|
GSK3 phosphorylation of the voltage-gated sodium (Nav) channel in experimental models of vulnerability to depression-like behavior |
|
|
228 | (1) |
|
GSK3 and voltage-gated potassium (Kv) channels |
|
|
228 | (1) |
|
Functional implications of GSK-3-dependent Kv4.2 phosphorylation |
|
|
229 | (1) |
|
GSK3 and Kv channels in experimental models of depression-like behaviors |
|
|
229 | (1) |
|
|
229 | (3) |
|
|
232 | (3) |
|
22 Sortilin/neurotensin receptor-3 and its derived peptides in depression |
|
|
235 | (8) |
|
|
|
|
|
235 | (1) |
|
How TREK-1 became a target in depression |
|
|
236 | (1) |
|
How sortilin was shown to be involved in depression |
|
|
236 | (1) |
|
Spadin and spadin analogs are selective fast-acting antidepressants |
|
|
237 | (1) |
|
Posttranslational products of NTSR3/sortilin as biomarkers |
|
|
238 | (1) |
|
The role of spadin as a link between obesity/diabetes and depression |
|
|
238 | (1) |
|
|
238 | (1) |
|
|
239 | (4) |
|
23 Implication of Wnt/beta-catenin signaling and its components in depression and neuropsychiatric disorders |
|
|
243 | (12) |
|
|
|
|
|
243 | (1) |
|
The canonical Wnt signaling pathway |
|
|
244 | (1) |
|
Noncanonical Wnt signaling pathway |
|
|
244 | (1) |
|
|
244 | (1) |
|
|
244 | (1) |
|
Wnt/p-catenin signaling components in depression |
|
|
244 | (2) |
|
|
246 | (1) |
|
|
247 | (1) |
|
|
248 | (1) |
|
|
248 | (1) |
|
Crosstalk between neurogenesis and Wnt signaling in depression and psychiatric disorders |
|
|
249 | (1) |
|
Antidepressants utilize Wnt signaling and its components for the action |
|
|
250 | (1) |
|
|
251 | (1) |
|
|
252 | (3) |
|
24 The prefrontal cortex in depression: Use of proteomics |
|
|
255 | (12) |
|
|
|
|
|
|
255 | (1) |
|
OMICS allowed a new insight into neuronal phenotype |
|
|
256 | (1) |
|
The basics of proteomic studies |
|
|
257 | (1) |
|
Proteomic studies in depression research |
|
|
258 | (1) |
|
Proteome changes in depression |
|
|
258 | (3) |
|
Limitations and perspectives |
|
|
261 | (1) |
|
|
262 | (5) |
|
Part III Neurological and imaging features |
|
|
|
25 How brain single photon emission computed topography imaging informs the diagnosis and treatment of mood disorders |
|
|
267 | (10) |
|
|
|
|
|
|
|
|
267 | (1) |
|
Imaging does not match the DSM, but can enhance it |
|
|
268 | (1) |
|
|
268 | (1) |
|
SPECT mood disorder literature |
|
|
269 | (1) |
|
|
269 | (1) |
|
|
269 | (1) |
|
Overall decreased perfusion |
|
|
270 | (1) |
|
|
271 | (1) |
|
Cognitive disorders vs depression |
|
|
271 | (1) |
|
How SPECT changes clinical practice and may improve outcomes |
|
|
272 | (1) |
|
SPECT, mood disorders, and treatment response |
|
|
272 | (1) |
|
|
273 | (4) |
|
26 Resting-state functional magnetic resonance imaging (rsfMRI) in bipolar and unipolar depression |
|
|
277 | (24) |
|
|
|
|
|
277 | (1) |
|
A framework for synthesizing rsfMRI results: Distributed functional networks |
|
|
277 | (1) |
|
Resting-state functional connectivity in unipolar depression |
|
|
278 | (9) |
|
Default mode network connectivity |
|
|
278 | (8) |
|
Salience network functional connectivity |
|
|
286 | (1) |
|
Resting-state functional connectivity in bipolar depression |
|
|
287 | (7) |
|
Default mode network connectivity |
|
|
287 | (5) |
|
Salience network connectivity |
|
|
292 | (2) |
|
Somatomotor network connectivity |
|
|
294 | (1) |
|
Functional connectivity differences between unipolar and bipolar depression |
|
|
294 | (2) |
|
Challenges to interpretation of resting-state studies |
|
|
296 | (1) |
|
|
296 | (1) |
|
|
297 | (4) |
|
27 Linking amygdala blood oxygenation-level-dependent (BOLD) activity and frontal EEC in depression |
|
|
301 | (10) |
|
|
|
|
301 | (1) |
|
Emotion regulation system |
|
|
301 | (1) |
|
Emotion regulation in depression |
|
|
302 | (1) |
|
Frontal EEC asymmetry and depression |
|
|
302 | (1) |
|
Linking amygdala BOLD activity and frontal EEC |
|
|
303 | (1) |
|
Amygdala real-time fMRI neurofeedback with simultaneous EEG |
|
|
303 | (1) |
|
EEG activity during the real-time fMRI neurofeedback procedure |
|
|
304 | (1) |
|
Frontal EEG asymmetry changes and depression severity |
|
|
305 | (1) |
|
EEG coherence enhancement and depression severity |
|
|
306 | (1) |
|
Correlations of amygdala BOLD activity and frontal EEG asymmetry |
|
|
306 | (1) |
|
|
307 | (2) |
|
|
309 | (2) |
|
28 The rostromedial tegmental nucleus: Features and links with alcohol and depression |
|
|
311 | (12) |
|
|
|
|
|
|
311 | (1) |
|
RMTg: Characteristics, inputs, and outputs associated with alcohol and depression |
|
|
312 | (3) |
|
RMTg afferents: Alcohol and depression |
|
|
313 | (1) |
|
RMTg efferents: Alcohol and depression |
|
|
314 | (1) |
|
RMTg activity in alcohol consumption and depression |
|
|
315 | (3) |
|
RMTg activity and alcohol use |
|
|
315 | (1) |
|
RMTg activity and depression |
|
|
315 | (3) |
|
Role of the RMTg in alcohol withdrawal-induced negative affect |
|
|
318 | (1) |
|
|
319 | (1) |
|
|
319 | (4) |
|
29 Human serotonergic neurons, selective serotonin reuptake inhibitor (SSRI) resistance and major depressive disorder |
|
|
323 | (8) |
|
|
|
|
|
323 | (1) |
|
|
324 | (1) |
|
Generating human serotonergic neurons |
|
|
324 | (2) |
|
Studying serotonergic neurotransmission in patient serotonergic neurons |
|
|
326 | (2) |
|
Studying serotonergic neurotransmission in patient cortical neurons |
|
|
328 | (1) |
|
|
328 | (1) |
|
|
329 | (1) |
|
|
330 | (1) |
|
30 Role of nesfatin-1 in major depression |
|
|
331 | (10) |
|
|
|
|
331 | (1) |
|
Structure and distribution of NUCB protein family |
|
|
331 | (1) |
|
Molecular structure of nesfatin-1 |
|
|
332 | (1) |
|
Distribution and effects of nesfatin-1 |
|
|
333 | (1) |
|
Nesfatin-1 and psychiatric disorders |
|
|
334 | (1) |
|
Nesfatin-1 and depression |
|
|
334 | (4) |
|
|
338 | (3) |
|
31 Impact of NGF signaling on neuroplasticity during depression: Insights in neuroplasticity-dependent therapeutic approaches |
|
|
341 | (10) |
|
|
|
|
|
|
341 | (1) |
|
Changes in neuroplasticity during the pathophysiology of depression |
|
|
342 | (1) |
|
Neuronal plasticity: Growth and change in depression |
|
|
342 | (1) |
|
NGF and neuroplasticity: The evidence |
|
|
342 | (1) |
|
Role of NGF in the plasticity of hippocampal and basal forebrain cholinergic neurons |
|
|
342 | (1) |
|
NGF dysregulation in depression |
|
|
343 | (1) |
|
|
343 | (1) |
|
|
343 | (1) |
|
NGF regulation in antidepressants treatment |
|
|
343 | (2) |
|
New perspectives for refining future treatment approaches: Neuroplasticity-dependent therapeutic approaches |
|
|
345 | (1) |
|
|
345 | (3) |
|
|
348 | (1) |
|
|
348 | (3) |
|
32 Inherited depression and psychological disorders and mental illness by germ cells and their memory |
|
|
351 | (10) |
|
|
|
|
351 | (1) |
|
|
351 | (1) |
|
Depression and degradation of germ cells |
|
|
351 | (1) |
|
|
351 | (1) |
|
Do the same causes produce the same effects in humans? |
|
|
352 | (1) |
|
Wartime, depression, and germ cells |
|
|
352 | (1) |
|
Psychological and environmental factors and female-male germ cells-fertility |
|
|
352 | (1) |
|
Transmission of trauma via germ cells |
|
|
352 | (1) |
|
|
353 | (1) |
|
Exercise, nutritional status, seasonal variations, and germ cells |
|
|
353 | (1) |
|
What is happening inside and beyond the uterus? |
|
|
353 | (1) |
|
Psychotherapy and sexual behavior |
|
|
353 | (1) |
|
Cognitive/physical activities and sexual behavior |
|
|
354 | (1) |
|
Relaxation and music/dance therapy |
|
|
354 | (1) |
|
|
354 | (1) |
|
|
355 | (1) |
|
Disclosure of potential conflicts of interest |
|
|
356 | (1) |
|
|
356 | (5) |
|
Part IV Behaviour and psychopathological effects |
|
|
|
33 Cognitive function and neurocognitive deficits in depression |
|
|
361 | (12) |
|
|
The "hot" and "cold" cognitive processes in depression |
|
|
361 | (1) |
|
Cognitive predictors of depression |
|
|
362 | (1) |
|
|
362 | (1) |
|
|
362 | (1) |
|
|
363 | (1) |
|
Cognitive function associated with a depressive episode |
|
|
363 | (1) |
|
|
363 | (1) |
|
|
364 | (1) |
|
|
364 | (1) |
|
Cognitive function following depressive episode remission |
|
|
364 | (3) |
|
|
364 | (2) |
|
|
366 | (1) |
|
|
367 | (1) |
|
Conclusion and future directions |
|
|
367 | (2) |
|
|
369 | (4) |
|
34 Cognitive and interpersonal contributors to relationship distress and depression: A review of the dyadic partner-schema model |
|
|
373 | (8) |
|
|
|
|
|
373 | (1) |
|
An overview of the dyadic partner-schema model |
|
|
373 | (4) |
|
Partner-schemas are key contributors to ongoing cognitions and behaviors toward romantic partners |
|
|
374 | (1) |
|
Depressive behaviors occur within a dyadic context |
|
|
375 | (1) |
|
Dysfunctional dyadic interactions impact present and future relationship distress and depression |
|
|
376 | (1) |
|
There is a reciprocal relationship between distress and depression |
|
|
376 | (1) |
|
Self- and partner-schema structures become consolidated over time as a result of negative partner interactions |
|
|
377 | (1) |
|
Clinical implications of the dyadic partner-schema model |
|
|
377 | (1) |
|
Directions for future research |
|
|
378 | (1) |
|
|
378 | (1) |
|
|
379 | (1) |
|
|
379 | (2) |
|
35 Cognitive vulnerability to depression in adolescence |
|
|
381 | (8) |
|
|
|
|
|
381 | (1) |
|
Developmental antecedents to cognitive vulnerability to depression |
|
|
381 | (1) |
|
Childhood maltreatment and cognitive vulnerability to depression |
|
|
382 | (1) |
|
Peer victimization and cognitive vulnerability to depression |
|
|
382 | (1) |
|
Limitations of the research on early life influences of cognitive vulnerability to depression |
|
|
383 | (1) |
|
Neurobiological findings for early life adversities |
|
|
383 | (1) |
|
Neurobiological findings for cognitive vulnerability to depression |
|
|
383 | (1) |
|
Conclusion and future directions |
|
|
384 | (1) |
|
|
385 | (4) |
|
36 Determining the cognitive performance in the first episode of depression |
|
|
389 | (8) |
|
|
|
|
389 | (1) |
|
Cognitive dysfunction in MDD |
|
|
389 | (1) |
|
A brief history of cognitive dysfunction in MDD |
|
|
390 | (1) |
|
Impact of cognitive dysfunction in MDD |
|
|
390 | (1) |
|
Cognitive dysfunction in the first episode of MDD |
|
|
391 | (2) |
|
|
391 | (2) |
|
|
393 | (1) |
|
|
393 | (2) |
|
|
395 | (2) |
|
37 Body image and depression |
|
|
397 | (8) |
|
Paivi Pylvanainen (Maria) |
|
|
|
|
|
|
397 | (1) |
|
Tripartite model of body image |
|
|
397 | (1) |
|
Reciprocal shaping: Body image is shaped by interaction and body image shapes interaction |
|
|
398 | (1) |
|
Systems view: The neurological layers of embodiment |
|
|
398 | (1) |
|
|
399 | (1) |
|
Studies of the body image in patients with depression |
|
|
399 | (1) |
|
Discomfort in sensing the body |
|
|
400 | (1) |
|
Body memory contents of the depressed patients' body image |
|
|
400 | (1) |
|
Body image quality and recovery from depression |
|
|
401 | (1) |
|
Addressing and accepting body image contents in the treatment ctf depression |
|
|
401 | (1) |
|
Dance movement therapy in the treatment of patients with depression |
|
|
402 | (1) |
|
|
403 | (2) |
|
38 Sleep, anxiety, and depression |
|
|
405 | (10) |
|
|
|
|
405 | (1) |
|
|
405 | (1) |
|
|
406 | (1) |
|
|
406 | (1) |
|
Available treatments for insomnia |
|
|
407 | (2) |
|
|
409 | (1) |
|
Treatments for anxiety disorders |
|
|
409 | (2) |
|
Mechanisms of sleep, anxiety, and depression |
|
|
411 | (1) |
|
|
411 | (1) |
|
|
412 | (3) |
|
39 Depression, anxiety, and quality of life |
|
|
415 | (10) |
|
|
|
|
415 | (1) |
|
Measures of qualify of life |
|
|
415 | (1) |
|
Depression and quality of life |
|
|
416 | (2) |
|
MDD and bipolar depression |
|
|
416 | (1) |
|
MDD vs bipolar depression |
|
|
416 | (1) |
|
Depression comorbid with other psychiatric disorders |
|
|
416 | (1) |
|
Depression with medical conditions |
|
|
416 | (2) |
|
Effect of treatment for depression on quality of life |
|
|
418 | (1) |
|
Pharmacological treatments for MDD and bipolar depression |
|
|
418 | (1) |
|
|
418 | (1) |
|
Antidepressant plus psychotherapy |
|
|
418 | (1) |
|
Electroconvulsive therapy |
|
|
418 | (1) |
|
Depression in medical conditions |
|
|
419 | (1) |
|
Anxiety and quality of life |
|
|
419 | (2) |
|
Generalized anxiety disorder |
|
|
419 | (1) |
|
|
419 | (1) |
|
|
420 | (1) |
|
Anxiety with medical conditions |
|
|
421 | (1) |
|
Effect of treatment for anxiety on quality of life |
|
|
421 | (1) |
|
Pharmacological treatments |
|
|
421 | (1) |
|
|
421 | (1) |
|
Anxiety in medical conditions |
|
|
421 | (1) |
|
|
421 | (1) |
|
|
422 | (3) |
|
40 Reward processing and depression: Current findings and future directions |
|
|
425 | (10) |
|
|
|
|
|
425 | (1) |
|
Theory linking reward processing and depression |
|
|
425 | (2) |
|
Reward processing and depression: A review of behavioral studies |
|
|
427 | (1) |
|
An ERP measure of reward processing |
|
|
427 | (1) |
|
Reward processing and depression: A review of ERP studies |
|
|
427 | (1) |
|
fMRI measurement of reward processing |
|
|
428 | (1) |
|
Reward processing and depression: A review of fMRI studies |
|
|
429 | (1) |
|
Life stress, reward processing, and depression |
|
|
430 | (1) |
|
Conclusion and future directions |
|
|
430 | (2) |
|
|
432 | (3) |
|
41 Sexual functioning in depression |
|
|
435 | (18) |
|
|
|
|
435 | (1) |
|
The problem statement: Sexual dysfunction in depressed individuals |
|
|
435 | (1) |
|
Pathophysiology of sexual dysfunction in depression |
|
|
436 | (1) |
|
Incidence and pathophysiology of TESD/antidepressant-induced sexual dysfunction |
|
|
436 | (1) |
|
Impact of sexual dysfunction on depression |
|
|
437 | (1) |
|
Risk factors for developing sexual dysfunction during antidepressant therapy |
|
|
437 | (1) |
|
Assessment of sexual functioning in patients with depression |
|
|
437 | (4) |
|
Management of sexual dysfunctions in depression |
|
|
441 | (4) |
|
|
445 | (1) |
|
|
445 | (8) |
|
Part V Diet, nutrition and botanicals |
|
|
|
42 Linking dietary glycemic index and depression |
|
|
453 | (10) |
|
|
|
|
453 | (1) |
|
Carbohydrates and glycemic index |
|
|
453 | (1) |
|
Glycemic responses and depression |
|
|
454 | (1) |
|
|
455 | (3) |
|
|
458 | (1) |
|
|
458 | (1) |
|
|
458 | (2) |
|
|
460 | (3) |
|
43 Gut microbiota and depression |
|
|
463 | (10) |
|
|
|
|
463 | (1) |
|
Gut microbiota and brain communication |
|
|
463 | (3) |
|
Effect of stress and depression on gut microbiota |
|
|
464 | (1) |
|
Effect of gut microbiota on depressive disorder |
|
|
464 | (1) |
|
Effect of changes in gut microbiota on depression (animal studies) |
|
|
465 | (1) |
|
Association between gut microbiota and depression (human studies) |
|
|
465 | (1) |
|
|
466 | (4) |
|
|
470 | (3) |
|
44 Linking dietary methyl donors, maternal separation, and depression |
|
|
473 | (12) |
|
|
|
|
|
|
473 | (1) |
|
Experimental models of depression based on stress in perinatal life |
|
|
473 | (3) |
|
|
473 | (1) |
|
Maternal separation and prenatal stress |
|
|
474 | (1) |
|
Epigenetic mechanisms in the context of depression |
|
|
474 | (2) |
|
Methyl donors and depression |
|
|
476 | (2) |
|
|
477 | (1) |
|
|
477 | (1) |
|
|
478 | (1) |
|
|
478 | (1) |
|
|
478 | (1) |
|
Mutations related to depression in genes of one-carbon metabolism |
|
|
478 | (1) |
|
|
479 | (2) |
|
|
481 | (4) |
|
45 Convolvulus pluricaulis usage and depression |
|
|
485 | (8) |
|
|
|
|
485 | (1) |
|
|
485 | (1) |
|
|
485 | (1) |
|
|
486 | (1) |
|
|
486 | (1) |
|
Reduced neurogenesis and neuroplasticity |
|
|
486 | (1) |
|
|
486 | (1) |
|
Current synthetic treatment for depression |
|
|
486 | (1) |
|
Introduction to herbal medicines |
|
|
487 | (1) |
|
|
487 | (1) |
|
Scientific classification |
|
|
487 | (1) |
|
|
488 | (1) |
|
Pharmacological activities of C. pluricaulis |
|
|
488 | (1) |
|
Effect of C. pluricaulis extract (CPE) in the mouse forced swim and tail suspension tests |
|
|
488 | (2) |
|
Effect of C. pluricaulis extract (CPE) behavior induced by chronic unpredictable mild stress in rat |
|
|
490 | (1) |
|
Effect of C. pluricaulis against H2O2-induced neurotoxicity in SH-SY5Y human neuronal cells |
|
|
490 | (1) |
|
Effect of scopoletin, phytochemical constituent of C. pluricaulis in tail suspension tests |
|
|
490 | (1) |
|
Effect of Kaempferol, a phytochemical constituent of C. pluricaulis in TST and FST |
|
|
490 | (1) |
|
|
490 | (1) |
|
|
491 | (2) |
|
46 Antidepressant activity of Crocus sativus L. and its main constituents: A review |
|
|
493 | (10) |
|
|
|
|
|
493 | (1) |
|
Antidepressant activity of saffron |
|
|
493 | (4) |
|
|
493 | (1) |
|
|
494 | (3) |
|
Antidepressant activity of saffron constituents and its bioactive fractions |
|
|
497 | (1) |
|
|
497 | (1) |
|
|
498 | (1) |
|
|
498 | (1) |
|
|
498 | (1) |
|
Bioactive fractions of C. sativus L. |
|
|
498 | (1) |
|
|
499 | (1) |
|
|
500 | (3) |
|
47 Mechanisms of action of herbal antidepressants |
|
|
503 | (16) |
|
Mahboobeh Ghasemzadeh Rahbardar |
|
|
|
|
503 | (1) |
|
|
504 | (10) |
|
Asparagus racemosus (Satawari) |
|
|
505 | (1) |
|
|
505 | (1) |
|
Berberis aristata (Indian Barberry) |
|
|
505 | (1) |
|
Camellia sinensis (Tea plant) |
|
|
505 | (1) |
|
Cimicifuga racemosa L. (Black Cohosh) |
|
|
506 | (1) |
|
|
507 | (1) |
|
|
508 | (1) |
|
Epimedium brevicornum (Bishop's hat) |
|
|
508 | (1) |
|
|
508 | (1) |
|
Glycyrrhiza glabra L. (Licorice) |
|
|
508 | (2) |
|
Hordeum vulgare L. (Barley) |
|
|
510 | (1) |
|
Hypericum perforatum (St. John's Wort) |
|
|
510 | (1) |
|
Magnolia officinalis (Magnolia bark) |
|
|
510 | (1) |
|
Mitragyna speciosa (Kratom) |
|
|
510 | (1) |
|
Morinda officinalis (Indian mulberry) |
|
|
510 | (1) |
|
Paeonia lactiflora Pall (Garden peony) |
|
|
510 | (1) |
|
Polygalasa bulosa (Timutu-pinheirinho) |
|
|
511 | (1) |
|
Rhodiola rosea (Roseroot) |
|
|
512 | (1) |
|
Rosmarinus officinalis L. (Rosemary) |
|
|
512 | (1) |
|
Schinus molle (Peruvian pepper) |
|
|
512 | (1) |
|
Siphocampylus verticillatus (Siphocampylus) |
|
|
512 | (1) |
|
Tabebuia avellanedae (Pink Tabebuia) |
|
|
513 | (1) |
|
Tinospora cordifolia (Guduchi) |
|
|
514 | (1) |
|
Zingiber officinale (G i nger) |
|
|
514 | (1) |
|
|
514 | (1) |
|
|
515 | (4) |
|
48 Antidepressant-like effects and mechanisms of the herbal formula Xiaochaihutang in depression |
|
|
519 | (12) |
|
|
|
|
|
519 | (1) |
|
Effects of XCHT on depressive animal models |
|
|
520 | (2) |
|
Effects of XCHT on CUMS rats |
|
|
520 | (1) |
|
Effects of XCHT on CSIS mice |
|
|
520 | (1) |
|
Effects of XCHT on CORT mice |
|
|
521 | (1) |
|
Effects of XCHT on OVX-CUMS mice |
|
|
521 | (1) |
|
Antidepressant mechanisms of XCHT |
|
|
522 | (3) |
|
|
522 | (1) |
|
|
522 | (1) |
|
|
523 | (1) |
|
|
524 | (1) |
|
|
525 | (2) |
|
|
527 | (4) |
|
|
|
49 Recommended resources on the neuroscience of depression: Genetics, cell biology, neurology, behavior, and diet |
|
|
531 | (8) |
|
|
|
|
|
531 | (1) |
|
|
531 | (6) |
|
|
537 | (1) |
|
|
537 | (2) |
Index |
|
539 | |